Seoul National University Hospital is running a clinical trial to test a drug called Tenofovir to treat Burkitt's, asubtype of Non-Hodgkin's Lymphoma. The objective of this study is to analyze factors affecting Hepatitis B Virus (HBV) reactivation in anti-HBc positive patients with Non-Hodgkin's lymphoma treated with rituximab and compare HBV reactivation rates by duration of prophylactic treatment with tenofovir to contribute to the establishment of an effective prevention strategy.
The drug is Tenofovir.
| Study Type : |
Interventional (Clinical Trial) |
| Estimated Enrollment : |
90 participants |
| Allocation: |
Randomized |
| Intervention Model: |
Parallel Assignment |
| Masking: |
None (Open Label) |
| Primary Purpose: |
Prevention |
| Official Title: |
A Multicenter Study to Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Patients With Isolated Anti-HBc-positivity Who Will be Treated With Rituximab Based Chemotherapy |
| Actual Study Start Date : |
November 2015 |
| Estimated Primary Completion Date : |
June 2018 |
| Estimated Study Completion Date : |
September 2018 |
For enrollment please visit www.clinicaltrials.gov.
